Georg Popp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georg Popp has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Eva Ehrentreich-Förster
Bioanalytics and Bioprocesses Branch, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Am Mühlenberg 13, 14476 Potsdam-Golm, Germany
1 shared publication - Joachim Beige
Kuratorium for Dialysis and Kidney Transplantation , Neu-Isenburg
1 shared publication - Johannes Wolf
Department of Laboratory Medicine, Hospital St. Georg, 04129 Leipzig, Germany
1 shared publication - Karolin Kern
Department Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstr. 1, 04103 Leipzig, Germany
1 shared publication - Lisa Jöckel
Fraunhofer Institute for Experimental Software Engineering IESE
1 shared publication - Lisbeth Ramirez-Caballero
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstr. 1, 04103 Leipzig, Germany
1 shared publication
Latest Publications
- Open Access
Uncertainty Wrapper in the medical domain: Establishing transparent uncertainty quantification for opaque machine learning models in practice
When systems use data-based models that are based on machine learning (ML), errors in their results cannot be ruled out. This is particularly critical if it remains unclear to the user how these models arrived at their decisions and if errors can have safety-relevant consequences, as is often the case in the medical field. In such cases, the use of dependable methods to quantify the uncertainty remaining in a result allows the user to make an informed decision about further usage and draw possible conclusions based on a given result. This paper demonstrates the applicability and practical utility of the Uncertainty Wrapper using flow cytometry as an application from the medical field that can benefit from the use of ML models in conjunction with dependable and transparent uncertainty quantification.
Open AccessUncertainty Wrapper in the medical domain: Establishing transparent uncertainty quantification for opaque machine learning models in practice
When systems use data-based models that are based on machine learning (ML), errors in their results cannot be ruled out. This is particularly critical if it remains unclear to the user how these models arrived at their decisions and if errors can have safety-relevant consequences, as is often the case in the medical field. In such cases, the use of dependable methods to quantify the uncertainty remaining in a result allows the user to make an informed decision about further usage and draw possible conclusions based on a given result. This paper demonstrates the applicability and practical utility of the Uncertainty Wrapper using flow cytometry as an application from the medical field that can benefit from the use of ML models in conjunction with dependable and transparent uncertainty quantification.
- Open Access
Detection of Antibodies against Endemic and SARS-CoV-2 Coronaviruses with Short Peptide Epitopes
(1) Background: Coronavirus proteins are quite conserved amongst endemic strains (eCoV) and SARS-CoV-2. We aimed to evaluate whether peptide epitopes might serve as useful diagnostic biomarkers to stratify previous infections and COVID-19. (2) Methods: Peptide epitopes were identified at an amino acid resolution that applied a novel statistical approach to generate data sets of potential antibody binding peptides. (3) Results: Data sets from more than 120 COVID-19 or eCoV-infected patients, as well as vaccinated persons, have been used to generate data sets that have been used to search in silico for potential epitopes in proteins of SARS-CoV-2 and eCoV. Peptide epitopes were validated with >300 serum samples in synthetic peptide micro arrays and epitopes specific for different viruses, in addition to the identified cross reactive epitopes. (4) Conclusions: Most patients develop antibodies against non-structural proteins, which are useful general markers for recent infections. However, there are differences in the epitope patterns of COVID-19, and eCoV, and the S-protein vaccine, which can only be explained by a high degree of cross-reactivity between the viruses, a pre-existing immune response against some epitopes, and even an alternate processing of the vaccine proteins.
Open AccessDetection of Antibodies against Endemic and SARS-CoV-2 Coronaviruses with Short Peptide Epitopes
(1) Background: Coronavirus proteins are quite conserved amongst endemic strains (eCoV) and SARS-CoV-2. We aimed to evaluate whether peptide epitopes might serve as useful diagnostic biomarkers to stratify previous infections and COVID-19. (2) Methods: Peptide epitopes were identified at an amino acid resolution that applied a novel statistical approach to generate data sets of potential antibody binding peptides. (3) Results: Data sets from more than 120 COVID-19 or eCoV-infected patients, as well as vaccinated persons, have been used to generate data sets that have been used to search in silico for potential epitopes in proteins of SARS-CoV-2 and eCoV. Peptide epitopes were validated with >300 serum samples in synthetic peptide micro arrays and epitopes specific for different viruses, in addition to the identified cross reactive epitopes. (4) Conclusions: Most patients develop antibodies against non-structural proteins, which are useful general markers for recent infections. However, there are differences in the epitope patterns of COVID-19, and eCoV, and the S-protein vaccine, which can only be explained by a high degree of cross-reactivity between the viruses, a pre-existing immune response against some epitopes, and even an alternate processing of the vaccine proteins.